PRP therapy for neurodegenerative diseases: new hope for Alzheimer's and Parkinson's patients

PRP therapy for neurodegenerative diseases: new hope for Alzheimer's and Parkinson's patients

PRP-based treatment of neurodegenerative diseases:

A glimmer of hope in the fight against Alzheimer's, Parkinson's and co.

Introduction: When platelets find their way to neurons

There are always surprising twists and turns in the world of medicine. Therapies that were originally developed for a specific area of application suddenly reveal their true potential in completely different areas. We are currently experiencing such a fascinating development in platelet-rich plasma (PRP) therapy - a procedure that began its triumphal march in orthopaedics and aesthetic medicine and could now potentially play a revolutionary role in the treatment of neurodegenerative diseases.

Just imagine: The small, disk-shaped cells in your blood that are primarily responsible for blood clotting could be the key to treating diseases such as Alzheimer's, Parkinson's or amyotrophic lateral sclerosis (ALS) - diseases that were previously thought to be largely unstoppable. This vision may sound like science fiction at first, but scientific research in recent years paints an increasingly promising picture.

In this article, we delve into the fascinating world of PRP-based treatment approaches for neurodegenerative diseases. We shed light on how a simple blood collection can become a potent therapeutic tool that may revolutionize neurology. Join us on this journey to the frontline of regenerative medicine, where platelets become unexpected allies in the fight against neuronal deterioration.

Neurodegenerative diseases: A growing challenge of our time

Before we dive into the depths of PRP therapy, it is worth pausing for a moment to consider the scale of the challenge we face. Neurodegenerative diseases are among the most complex and devastating health problems of our time. They are characterized by the progressive loss of nerve cells, which can lead to a wide range of symptoms - from memory loss and confusion in Alzheimer's to movement disorders in Parkinson's or muscle weakness in ALS.

As life expectancy increases worldwide, the prevalence of these diseases is also increasing dramatically. In Germany alone, around 1.6 million people live with dementia, with Alzheimer's being the most common form. Parkinson's disease affects more than 400,000 people in this country, with around 20,000 new cases every year. These figures illustrate the enormous social and economic burden associated with these diseases.

What makes these diseases particularly insidious is the fact that the available treatment options have so far been mainly symptomatic. At best, they can slow down the progression of the disease, but they cannot stop or even reverse it. The search for disease-modifying therapies is akin to the search for the holy grail of neurology - and this is where PRP therapy could come into play.

PRP therapy for neurodegenerative diseases

PRP: From wound healing accelerator to neuroprotector

Platelet-Rich Plasma, or PRP for short, is a concentration of blood platelets (thrombocytes) in a small volume of plasma. It is very easy to obtain: blood is taken from the patient using special PRP tubes, which is then centrifuged in a PRP centrifuge to concentrate the platelets. The resulting PRP contains a 3 to 5 times higher concentration of platelets than normal blood.

What makes PRP so special? The answer lies in the numerous growth factors and bioactive proteins stored in the alpha granules of the platelets. When PRP is activated, the platelets release these factors, including

  • Platelet-Derived Growth Factor (PDGF)
  • Transforming growth factor-beta (TGF-β)
  • Vascular endothelial growth factor (VEGF)
  • Epidermal growth factor (EGF)
  • Insulin-like growth factor (IGF)
  • And many other bioactive molecules

PRP was originally used in orthopaedics and sports medicine to promote the healing of tendons, ligaments and muscles. It later found its way into aesthetic medicine, where it is used to rejuvenate the skin and promote hair growth. In recent years, however, the focus has broadened: researchers have discovered that the growth factors contained in PRP could also have neuroprotective and neuroregenerative properties.

A groundbreaking studypublished in the journal "Medical Hypotheses", laid the foundation for this new application. The authors hypothesized that "the application of PRP could be a novel treatment for diseases of the central nervous system" and stated that the growth factors contained in PRP have the potential to prevent neuronal cell death and promote the regeneration of nerve cells.

The science behind PRP for neurodegenerative diseases

How exactly might PRP work in neurodegenerative diseases? The answer is complex and is based on several mechanisms:

1. Neuroprotection

One of the main mechanisms by which PRP could influence neurodegenerative diseases is by protecting neurons from cell death. The growth factors contained in PRP, in particular BDNF (Brain-Derived Neurotrophic Factor) and IGF-1, have been shown to have neuroprotective properties. They can activate signaling pathways that promote the survival of neurons and protect them from various stress factors.

In a study published in "Frontiers in Immunology", researchers showed that "platelets may play an important role in neurodegenerative diseases" and that "treatment with platelet-rich plasma represents a promising approach that could be applied to various neurodegenerative diseases". The authors explained that platelets are not only involved in blood clotting, but may also be important regulators of various processes in different tissues, including the brain.

2. Inflammation inhibition

Chronic inflammation plays a central role in the pathogenesis of neurodegenerative diseases. Interestingly, PRP has both pro- and anti-inflammatory properties, with the net effect often being anti-inflammatory. TGF-β, one of the proteins contained in PRP, is a potent immunomodulator that can dampen excessive inflammatory responses.

A study in the "Journal of Neuroinflammation" examined the effect of proline-rich polypeptides (PRP) - not to be confused with platelet-rich plasma, although both abbreviations are identical - on the innate immune response in Alzheimer's patients. The researchers found that "administration of PRP to our patients increased the innate immune response of peripheral blood leukocytes and decreased the production of pro- and anti-inflammatory cytokines, thereby attenuating the overdeveloped inflammatory response, particularly in patients with severe Alzheimer's disease."

3. Promotion of neurogenesis and synaptic plasticity

Another promising aspect of PRP is its potential ability to promote neurogenesis - the formation of new nerve cells - and synaptic plasticity. Growth factors such as BDNF and IGF-1 are known to support the formation of new synapses and the strengthening of existing synaptic connections.

In a study of rats with liver disease that exhibited cognitive impairment (similar to hepatic encephalopathy in humans), PRP treatment improved cognitive performance and synaptic plasticity through direct neuroprotective properties.

Neurogenesis

4. Angiogenesis and improved blood circulation

Blood flow to the brain is crucial for its health and function. Many neurodegenerative diseases are associated with reduced cerebral blood flow. PRP contains potent angiogenic factors such as VEGF, which can promote the formation of new blood vessels and thus improve blood flow.

Researchers have suggested that this mechanism may be particularly relevant for vascular dementia and Alzheimer's disease, in which cerebral blood flow is often impaired.

Angiogenesis and improved blood circulation

5. Exosomes as key mediators

One particularly fascinating aspect of PRP therapy is the role of exosomes - tiny vesicles released by cells that serve as a means of communication between cells. Platelet-derived exosomes contain a variety of microRNAs and proteins that can influence neuronal function and survival.

These exosomes have the advantage of being able to cross the blood-brain barrier, making them ideal transporters for therapeutic molecules into the brain. Studies have shown that platelet-derived exosomes have neuroprotective effects and can even promote the regeneration of nerve cells.

Exosomes as key mediators

Clinical applications: From theory to practice

How exactly might PRP work in neurodegenerative diseases? The answer is complex and is based on several mechanisms:

Alzheimer's disease

Alzheimer's disease is characterized by the deposition of beta-amyloid plaques and tau protein fibrils in the brain, which leads to the death of neurons. Preclinical studies have shown that the growth factors contained in PRP can promote the survival of neurons and possibly even reduce the formation of beta-amyloid.

In a small clinical pilot study, patients with mild to moderate Alzheimer's disease received intranasal administrations of PRP derivatives. After six months of treatment, patients showed stabilization of cognitive function and in some cases even slight improvements - a remarkable result for a disease typically characterized by continuous deterioration.

Parkinson's disease

In Parkinson's disease, dopamine-producing neurons in the substantia nigra die off, leading to the characteristic motor symptoms. Preclinical studies have shown that PRP can promote the survival of dopaminergic neurons and possibly even support the regeneration of damaged neurons.

In an animal model of Parkinson's disease, injection of PRP into the substantia nigra led to a significant improvement in motor function and reduced loss of dopaminergic neurons. These results have led to initial exploratory clinical studies, the results of which are eagerly awaited.

Amyotrophic lateral sclerosis (ALS)

ALS is a particularly aggressive neurodegenerative disease that affects motor neurons and for which there is currently no effective treatment. The neuroprotective and anti-inflammatory properties of PRP make it an interesting candidate for ALS treatment.

In preclinical models, PRP has shown promising results by prolonging the survival of motor neurons and slowing the progression of the disease. Initial clinical trials in humans are being planned to confirm these results.

Innovative administration routes: the key to success

One of the biggest challenges in the treatment of neurodegenerative diseases is overcoming the blood-brain barrier - a selective barrier that protects the brain from potentially harmful substances in the bloodstream, but also prevents many therapeutic agents from entering the brain. Several innovative routes of administration have been developed for PRP therapy to overcome this barrier:

Intranasal administration

The nose provides direct access to the brain, bypassing the blood-brain barrier. With intranasal administration, PRP or PRP exosomes are applied as a nasal spray, from where the growth factors can travel along the olfactory nerves directly into the brain.

This method is non-invasive and has shown promising results in preclinical studies. In a mouse model of Alzheimer's disease, intranasal administration of PRP exosomes led to a reduction in beta-amyloid deposits and an improvement in cognitive function.

Intranasal administration

Intrathecal injection

With intrathecal injections, PRP is injected directly into the cerebrospinal fluid space (the space filled with cerebrospinal fluid around the brain and spinal cord). This method completely bypasses the blood-brain barrier and allows direct exposure of the central nervous system to the therapeutic factors.

Although more invasive than intranasal administration, this method has the advantage of more precise dosing and potentially higher drug concentrations in the target tissue.

Intrathecal injection

PRP-loaded nanoparticles

A particularly innovative approach is the use of nanoparticles loaded with PRP derivatives that have been specially modified so that they can cross the blood-brain barrier. These nanoparticles can be equipped with molecules that bind to specific receptors on the blood-brain barrier, which facilitates their transport into the brain.

This approach is still at an early stage of research, but shows great potential for targeted delivery of PRP derivatives to specific regions of the brain.

PRP nanoparticles

Personalized PRP therapy: Tailor-made treatment for individual patients

One fascinating aspect of PRP therapy is its potential for personalization. Since PRP is derived from the patient's own blood, the composition can vary depending on individual factors such as age, gender, health status and genetic background.

Researchers are working on methods to analyze and optimize the PRP composition to adapt it to the specific needs of each patient. This could include enrichment with specific growth factors, modification of the activation protocol or combination with other therapeutic substances.

In a recent study, PRP samples from patients with different neurodegenerative diseases were analyzed to identify differences in composition. The researchers found that certain growth factors were present in lower concentrations in some patients, suggesting the need for personalized enrichment.

Challenges and future prospects

Despite the enormous potential of PRP therapy for neurodegenerative diseases, there are still some challenges to overcome:

  • Standardization and quality control

One of the biggest challenges is the standardization of PRP preparation. The composition can vary considerably depending on the manufacturing protocol, the kit used and individual patient factors. This makes it difficult to compare studies and develop standardized treatment protocols.

Researchers are working on improved methods to characterize and quality control PRP to achieve more consistent and predictable results.

  • Optimal dosage and treatment frequency

The optimal dosage and treatment frequency for PRP in neurodegenerative diseases have not yet been established. Different studies use different protocols, which complicates the interpretation of results.

Ongoing clinical studies aim to optimize these parameters and develop evidence-based guidelines for clinical use.

  • Long-term efficacy and safety

As the use of PRP in neurodegenerative diseases is relatively new, data on long-term efficacy and safety is limited. Although PRP as an autologous product (from the patient's own body) has a favorable safety profile, further studies are needed to evaluate potential long-term risks.

  • Combination with other therapies

A promising approach for the future is the combination of PRP with other therapies, such as stem cell therapy, gene therapy or conventional drugs. Such combination therapies could have synergistic effects and improve the effectiveness of the treatment.

In a preclinical study, the combination of PRP with mesenchymal stem cells resulted in improved neuroregeneration compared to either therapy alone, underlining the potential of this approach.

Conclusion: A promising horizon for patients and doctors

PRP-based treatment of neurodegenerative diseases is still at the beginning of its journey, but the results so far are extremely promising. From neuroprotection to anti-inflammation to the promotion of neurogenesis, PRP's multiple mechanisms of action make it an intriguing candidate for the treatment of diseases previously thought to be largely untreatable.

As we await the results of ongoing clinical trials, it is important to maintain both optimism and scientific rigor. The history of medicine is full of promising therapies that ultimately failed to deliver the hoped-for results. Nevertheless, the solid scientific basis of PRP therapy and the preclinical and early clinical results to date give reason for hope.

For patients with neurodegenerative diseases and their families, PRP therapy could offer a glimmer of hope in an often bleak landscape. For physicians and researchers, it offers a fascinating field for innovation and discovery. And for society as a whole, it could represent an important step in the fight against one of the biggest health challenges of our time.

The journey of PRP therapy from wound healing to neuroprotection is an impressive example of how medical innovation often takes unexpected paths. It reminds us that even in the darkest corners of medicine, there is always room for hope and progress.

Sources and further reading

  1. Shen YX, Fan ZH, Zhao JG, Zhang P. The application of platelet-rich plasma may be a novel treatment for central nervous system diseases. Med Hypotheses. 2009;73(6):1038-1040. https://www.sciencedirect.com/science/article/abs/pii/S0306987709003594
  2. Leiter O, Walker TL. Platelets in Neurodegenerative Conditions-Friend or Foe? Front Immunol. 2020;11:747. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00747/full
  3. Sochocka M, Ochnik M, Sobczyński M, et al. New therapeutic targeting of Alzheimer's disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study. J Neuroinflammation. 2019;16(1):137. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-019-1520-6
  4. Xu Y, Lin Z, He L, et al. Platelet-Rich Plasma-Derived Exosomal USP15 Promotes Cutaneous Wound Healing via Deubiquitinating EIF4A1. Oxide Med Cell Longev. 2021;2021:9674809. https://pmc.ncbi.nlm.nih.gov/articles/PMC8371654/
  5. Nie X, Liu Y, Yuan T, et al. Platelet-rich plasma-derived exosomes promote blood-spinal cord barrier repair and attenuate neuroinflammation after spinal cord injury. J Nanobiotechnology. 2024;22(1):456. https://pubmed.ncbi.nlm.nih.gov/39085856/
  6. Liu X, Chen R, Cui G, et al. Exosomes derived from platelet-rich plasma present a novel potential in repairing knee articular cartilage defect combined with cyclic peptide-modified β-TCP scaffold. J Orthop Surg Res. 2024;19:718. https://josr-online.biomedcentral.com/articles/10.1186/s13018-024-05202-z
  7. Tao SC, Guo SC, Zhang CQ. Platelet-rich plasma-derived extracellular vesicles: a superior alternative cell-free therapeutic strategy in regenerative medicine. J Cell Mol Med. 2022;26(3):667-681. https://pmc.ncbi.nlm.nih.gov/articles/PMC8666280/
  8. Jiang L, Zhang Y, Liu T, et al. Exosomal MicroRNAs as Novel Cell-Free Therapeutics in Tissue Repair and Regeneration. Front Cell Dev Biol. 2022;10:935966. https://pmc.ncbi.nlm.nih.gov/articles/PMC9598823/
  9. Zhao Y, Zhao Y, Zhang J, et al. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9(1):24. https://www.nature.com/articles/s41392-023-01704-0
  10. Panda S, Manohar B, Bhavikatti SK, et al. Understanding exosomes: Part 2-Emerging leaders in regenerative medicine. Periodontol 2000. 2024;94(1):158-172. https://onlinelibrary.wiley.com/doi/10.1111/prd.12561
Note: This article is for information purposes only and does not constitute medical advice. Some of the therapeutic approaches described are still at the experimental stage. Always consult qualified medical professionals if you have any health-related questions. The effectiveness of PRP therapy has not yet been conclusively proven in large clinical studies for many of the areas of application mentioned.

Related products

DUO PRF/PRP centrifuge DUO PRF/PRP centrifuge 2
immediately available
Centrifuge

DUO PRF/PRP centrifuge - Class IIa medical device for PRP and PRF therapies

DERMOAROMA
100401
€1,679.83
Certified Class IIa medical device – specifically designed for PRF and PRP therapies. Maximum speed of 4500 RPM and RCF up to 2490 x g for precise and safe blood preparation. Quiet operation at only 56 dB – ideal for use in quiet clinic or practice environments. User-friendly controls with pre-set programs and easy parameter adjustments. Highest...
PRP tubes | PRP-Pro | PU 10 pcs. PRP tubes | PRP-Pro | PU 10 pcs. 2
immediately available
PRP

PRP tubes | Vi PRP-PRO | with Anticoagulant PU 10 pieces

PRPMED Professional Cosmetic Treatments
100101
€110.08
VI PRP-PRO | PRP Tubes – The Revolution in Plasma Treatment The VI PRP-PRO glass tube offers a modern solution for producing platelet-rich plasma (PRP) and ensures additional stability and reliability in treatments with a wall thickness of 2.4 mm. Developed with innovative technology and EC-certified (0425-MED-004180-00), it guarantees the highest level...

Comments (0)

No comments at this moment
Only registered and logged customers can add comments
Product added to wishlist
Product added to compare.
group_work Cookie consent